WILL-EMINCT06998524
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
At risk: Primary completion moved at least 5 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 22 versions: 19 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion pushed from Apr 30, 2027 to Oct 6, 2027
- Study completion pushed from Apr 30, 2029 to Sep 6, 2029
- Minor Study sites: 29 to 30
- Notable Eligibility criteria expanded, about 17 words
- Site details revised at 5 of 29 sites
- Minor Study sites: 28 to 29v19
- Minor Study sites: 27 to 28v17
- Study Status, Contacts/Locations, Referencesv16
- Minor Primary completion pushed from Mar 30, 2027 to Apr 30, 2027
- Study completion pushed from Mar 30, 2029 to Apr 30, 2029
- Minor Study sites: 26 to 27v12
- Minor Study sites: 24 to 26v11
- Minor Study sites: 21 to 24
- Primary completion date: Dec 31, 2026 to Mar 30, 2027
- Study completion date: Dec 31, 2028 to Mar 30, 2029
- Minor Study sites: 20 to 21v9
- Minor Study sites: 16 to 20v8
Notable Eligibility criteria expanded, about 22 wordsv7 Show 4 more changesShow less
- Enrollment target: 66 to 75
- Study sites: 13 to 16
- Primary completion date: Dec 15, 2027 to Dec 31, 2026
- Secondary endpoints: 23 to 25
- Minor Study sites: 12 to 13v6
- Minor Study sites: 9 to 12v5
- Minor Study sites: 7 to 9v4
- Minor Study sites: 1 to 7
- Study completion date: May 15, 2029 to Dec 31, 2028
- Start date changed from estimate of Jun 15, 2025 to Jun 27, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (25)
Show 20 moreShow less
Arms and interventions
Participants who are randomized to Arm A, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will receive emicizumab SC prophylaxis.
Participants who are randomized to Arm B, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will continue to receive their current SOC on-demand treatment until Week 24.
Participants who enroll in Arm C, taking SOC prophylactic treatment at the time of study entry and for at least 24 weeks of observation during the preceding NIS WP45335, will receive emicizumab SC prophylaxis.
Participants in Arms A and C who have completed 24 weeks of emicizumab prophylaxis and who derive benefit from emicizumab will have the opportunity to continue to receive emicizumab prophylaxis in the extension period. Participants in Arm B who have completed 24 weeks of SOC on-demand treatment will have the opportunity to receive emicizumab prophylaxis in the extension period.
Drugs: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
Sites
30 sites in 14 countries
United States 6, United Kingdom 4, Germany 3, Italy 3, Canada 2, France 2, Japan 2, Spain 2, Belgium 1, Colombia 1, Netherlands 1, Poland 1, South Africa 1, Sweden 1